This article is more than 5 years old. Information may no longer be current.

Ista reports 92% increase in third quarter revenue

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — Ista Pharmaceuticals recorded third quarter net revenue of $15.9 million, a 92% increase over the third quarter of 2006, according to a press release from the company. Net revenue also increased 17% over the second quarter of 2007, the release said.

Specifically, compared with the third quarter 2006, third quarter 2007 sales of Xibrom (bromfenac ophthalmic solution 0.09%) increased 117% to $11.3 million, Istalol (timolol maleate 0.5%) sales increased 43% to $3 million and Vitrase (hyaluronidase) sales increased 67% to $1.5 million.

Additionally, Ista's net loss for the quarter was $8.2 million, or $0.25 per share, an improvement compared with its net loss of $11.8 million, or $0.45 per share, for the third quarter 2006, according to the release.